Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
6
×
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
6
×
detroit blog main
detroit top stories
indiana blog main
6
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
6
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
fda
investing
vertex pharmaceuticals
amgen
cell therapy
deals
drugs
merck
pfizer
spark therapeutics
What
roundup
bio
drug
ahead
american
annual
asco
cancer
days
fda
new
society
time
advantages
alliance
ambien
approved
ash
attendees
attention
bar
biotech
blood
borne
branded
brings
bristol
buy
calls
camp’s
cancers
cash
changing
chicago
choices
city
clinical
color
combinations
commissioner
Language
unset
Current search:
roche
×
" boston blog main "
×
" clinical trials "
×
" indiana blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More